Medicine and Dentistry
Cancer Therapy
100%
Evaluation Study
100%
Gefitinib
100%
Oligoastrocytoma
100%
Inpatient
100%
Patient
85%
Glioblastoma
71%
Therapeutic Procedure
57%
Adverse Event
42%
Epidermal Growth Factor Receptor
42%
Progression Free Survival
28%
Exanthem
28%
Loose Feces
28%
Magnetic Resonance Imaging
14%
Surgery
14%
Overall Survival
14%
Radiation Therapy
14%
Fluorescence in Situ Hybridization
14%
Enzyme
14%
Patient History of Chemotherapy
14%
Dexamethasone
14%
Diarrhea
14%
Receptor Gene
14%
Epidermal Growth Factor Receptor Kinase Inhibitor
14%
Chemotherapeutic Agent
14%
Drug
14%
CYP3A4
14%
Gene
14%
Fatigue
14%
Population Dynamics
14%
Tissues
14%
Brain
14%
Adult
14%
Immunohistochemistry
14%
INIS
evaluation
100%
cancer
100%
patients
100%
astrocytomas
100%
glioblastomas
71%
growth factors
57%
receptors
57%
radiations
42%
amplification
42%
genes
28%
control
28%
mutations
28%
data
14%
tissues
14%
fluorescence
14%
nmr imaging
14%
drugs
14%
surgery
14%
adults
14%
comparative evaluations
14%
populations
14%
brain
14%
doses
14%
chemotherapy
14%
enzymes
14%
fatigue
14%
in-situ hybridization
14%
diarrhea
14%
dexamethasone
14%
Nursing and Health Professions
Evaluation Study
100%
Astrocytoma
100%
Cancer Therapy
100%
Gefitinib
100%
Glioblastoma
71%
Adverse Event
42%
Epidermal Growth Factor Receptor
42%
Progression Free Survival
28%
Control
28%
Rash
28%
Clinical Outcome
14%
Overall Survival
14%
Surgery
14%
Nuclear Magnetic Resonance Imaging
14%
Drug
14%
Dexamethasone
14%
Diarrhea
14%
Enzyme
14%
Radiotherapy
14%
Fatigue
14%
Fluorescence in Situ Hybridization
14%
Patient History of Chemotherapy
14%
Immunohistochemistry
14%
Device Material
14%
Time
14%
Dose
14%
Epidermal Growth Factor Receptor Kinase Inhibitor
14%
CYP3A4
14%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Gefitinib
100%
Astrocytoma
100%
Glioblastoma
71%
Adverse Event
42%
Epidermal Growth Factor Receptor
42%
Progression Free Survival
28%
Rash
28%
Loose Feces
28%
Overall Survival
14%
Enzyme
14%
Patient History of Chemotherapy
14%
Dexamethasone
14%
Diarrhea
14%
Epidermal Growth Factor Receptor Kinase Inhibitor
14%
CYP3A4
14%
Drug
14%
Fatigue
14%
Biochemistry, Genetics and Molecular Biology
Gefitinib
100%
Epidermal Growth Factor Receptor
57%
Mutation
42%
Radiation
42%
Progression Free Survival
28%
Fluorescence in Situ Hybridization
14%
Receptor Gene
14%
Lysozyme
14%
Overall Survival
14%
CYP3A4
14%
Dexamethasone
14%
Population Dynamics
14%
Growth Factor Receptor Inhibitor
14%
Magnetic Resonance Imaging
14%
Time
14%
Dose
14%